Fluorouracil

Generic Name
Fluorouracil
Brand Names
Actikerall, Carac, Efudex, Fluoroplex, Tolak
Drug Type
Small Molecule
Chemical Formula
C4H3FN2O2
CAS Number
51-21-8
Unique Ingredient Identifier
U3P01618RT
Background

A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication

For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions
Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
Associated Therapies
-
Clinical Trials
Related News

Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

First Posted Date
2021-02-21
Last Posted Date
2024-05-16
Lead Sponsor
Ning Jin
Target Recruit Count
13
Registration Number
NCT04761614
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis

First Posted Date
2021-02-21
Last Posted Date
2023-12-22
Lead Sponsor
University of California, Irvine
Target Recruit Count
35
Registration Number
NCT04762953
Locations
🇺🇸

Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States

A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms

First Posted Date
2021-02-16
Last Posted Date
2021-02-16
Lead Sponsor
Taizhou HoudeAoke Biomedical Co., Ltd.
Target Recruit Count
94
Registration Number
NCT04755543
Locations
🇨🇳

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

🇨🇳

Henan Cancer Hospital & Insititute, Zhengzhou, Henan, China

🇨🇳

Liaoning Cancer Hospital & Insititute, Shenyang, Liaoning, China

and more 2 locations

Onvansertib in Combination with Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants with Metastatic Pancreatic Ductal Adenocarcinoma

First Posted Date
2021-02-12
Last Posted Date
2024-11-20
Lead Sponsor
Cardiff Oncology
Target Recruit Count
43
Registration Number
NCT04752696
Locations
🇺🇸

Mayo Clinic Jacksonville, Jacksonville, Florida, United States

🇺🇸

Inova Schar Cancer Institute, Fairfax, Virginia, United States

🇺🇸

Mayo Clinic Rochester, Rochester, Minnesota, United States

and more 3 locations

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GS-3583 in Participants With Advanced Solid Tumors

First Posted Date
2021-02-10
Last Posted Date
2022-12-05
Lead Sponsor
Gilead Sciences
Target Recruit Count
13
Registration Number
NCT04747470
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

🇺🇸

NEXT oncology, San Antonio, Texas, United States

🇺🇸

START Midwest, Grand Rapids, Michigan, United States

and more 1 locations

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients with Gastric Cancer

First Posted Date
2021-02-09
Last Posted Date
2024-11-15
Lead Sponsor
National Cancer Center Hospital East
Target Recruit Count
43
Registration Number
NCT04745988
Locations
🇯🇵

National Cancer Center Hospital East, Kashiwa, Chiba, Japan

Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer

First Posted Date
2021-01-11
Last Posted Date
2024-01-18
Lead Sponsor
Jonsson Comprehensive Cancer Center
Target Recruit Count
25
Registration Number
NCT04703101
Locations
🇺🇸

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)

First Posted Date
2020-12-19
Last Posted Date
2023-03-02
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Target Recruit Count
36
Registration Number
NCT04675983
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, China

A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma

First Posted Date
2020-12-16
Last Posted Date
2020-12-21
Lead Sponsor
Benaroya Research Institute
Target Recruit Count
100
Registration Number
NCT04668976
Locations
🇺🇸

Virginia mason medical Center, Seattle, Washington, United States

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

First Posted Date
2020-12-10
Last Posted Date
2024-11-18
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
890
Registration Number
NCT04662710
Locations
🇺🇸

UCLA Hematology/Oncology - Santa Monica ( Site 0003), Los Angeles, California, United States

🇦🇺

Nepean Hospital ( Site 2305), Kingswood, New South Wales, Australia

🇺🇸

Mount Sinai Hospital ( Site 0051), New York, New York, United States

and more 174 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy